Patents Assigned to SuperGen, Inc.
-
Patent number: 6905669Abstract: Compositions and methods are provided for treating diseases associated with aberrant silencing of gene expression such as cancer by reestablishing the gene expression through inhibition of DNA hypomethylation and histone deacetylase. The method comprises: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.Type: GrantFiled: April 24, 2001Date of Patent: June 14, 2005Assignee: SuperGen, Inc.Inventor: Jorge F. DiMartino
-
Publication number: 20050059682Abstract: Compositions and methods for treatment of conditions related to the overexpression of EZH2, such as late stage prostate cancer, using a DNA methylation inhibitor and/or a histone deacetylase inhibitor, optionally in combination with an EZH2 antagonist and/or an antineoplastic agent, to specifically target diseases associated with EZH2 over-expression. Further provided are reagents and kits for treatment of EZH2 overexpression.Type: ApplicationFiled: September 12, 2003Publication date: March 17, 2005Applicant: SuperGen, Inc., a Delaware CorporationInventor: Joseph Rubinfeld
-
Publication number: 20050043225Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritation effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.Type: ApplicationFiled: August 11, 2004Publication date: February 24, 2005Applicant: SuperGen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6828346Abstract: Methods are provided for using paclitaxel for treating diseases associated with abnormal cell proliferation and angiogenesis. In particular, methods are provided for administration of paclitaxel formulated with vitamin E derivatives such as d-&agr;-tocopherol polyethylene glycol succinate to a cancer patient. By administering to a patient paclitaxel in a vehicle containing a solubilizer other than Cremophor, acute hypersensitivity caused by Cremophor can be avoided and therapeutic index of paclitaxel may also be increased through potentiation of anti-neoplastic effects by the vitamin E derivatives.Type: GrantFiled: January 23, 2003Date of Patent: December 7, 2004Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Howard Sands, Joseph Rubinfeld
-
Patent number: 6800616Abstract: Disclosed is a method of treating an HIV-infected host including administering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of treating an HIV-infected host including administering highly active antiretroviral therapy; and coadministering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount.Type: GrantFiled: February 26, 1998Date of Patent: October 5, 2004Assignee: SuperGen, Inc.Inventor: Simeon M. Wrenn, Jr.
-
Publication number: 20040167205Abstract: A method is provided for preparing a pharmaceutical composition comprising: taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen for a period of time, the exposure to the gas over the period of time causing an acidity of the polyoxyethylated castor oil to increase; and forming a pharmaceutical composition comprising the aged polyoxyethylated castor oil and a pharmaceutically active agent such as paclitaxel; wherein at least 80% of the potency of the pharmaceutically active agent is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40° C.Type: ApplicationFiled: February 18, 2004Publication date: August 26, 2004Applicant: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Joseph Rubinfeld, Sanjeev Redkar, Ashok Y. Gore
-
Publication number: 20040162263Abstract: Oral formulations of pharmaceuticals are provided with enhanced bioavailability by targeting specific regions of the gastrointestinal tract. Particularly, water soluble and acid-labile drugs such as cytidine analogs (e.g., decitabine) and 2′-deoxyadenosine analogs (e.g., pentostatin) are formulated with pH-sensitive polymers so that these drugs are preferably absorbed in the upper regions of the small intestine, such as the jejunum. In addition, drugs with poor oral bioavailability such as camptothecin compounds (e.g., 9-nitro-camptothecin) can also be formulated using similar strategies in order to significantly improve their oral bioavailability. These formulations can be used to treat a wide variety of diseases or conditions, such hematological disorders, benign tumors, cancer, restenosis, inflammatory diseases, and autoimmune diseases.Type: ApplicationFiled: October 31, 2003Publication date: August 19, 2004Applicant: SuperGen, Inc., a Delaware CorporationInventors: Howard Sands, Sanjeev Redkar, Harish Ravivarapu
-
Publication number: 20040127404Abstract: The present invention provides methods for treating a patient with an autoimmune disease by administering an inhibitor of adenosine deaminase (ADA) such as pentostatin and its analogs and derivatives.Type: ApplicationFiled: December 18, 2003Publication date: July 1, 2004Applicants: Board of Regents, The University of Texas System, Supergen, Inc.Inventors: Nam H. Dang, Timothy Enns
-
Patent number: 6756381Abstract: A polymorphic form of 9-nitrocamptothecin is provided, the polymorph being characterizable as having an IR spectrum with an absorption centered between 3625 cm−1 and 3675 cm−1 and containing more than a trace of water.Type: GrantFiled: February 21, 2002Date of Patent: June 29, 2004Assignee: SuperGen, Inc.Inventors: Sanjeev Redkar, Ashok Gore
-
Publication number: 20040116411Abstract: A method is provided for treating HIV infection using a combination therapy which includes a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, precursor of 20(S)-camptothecin and metabolite of 20(S)-camptothecin, in combination with a cocktail of antiretroviral drugs such as nucleoside reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, protease inhibitors, fusion inhibitors and integrase inhibitors. The method comprises administering highly active antiretroviral therapy (HAART); and co-administering to the HIV-infected host therapeutically effective amount of a compound selected from the group consisting of 20(S)-camptothecin, analog of 20(S)-camptothecin, derivative of 20(S)-camptothecin, precursor of 20(S)-camptothecin and metabolite of 20(S)-camptothecin.Type: ApplicationFiled: September 23, 2003Publication date: June 17, 2004Applicant: SuperGen, Inc., a Delaware CorporationInventors: Gerald Schochetman, Lucy Chang, Joseph Rubinfeld
-
Publication number: 20040109846Abstract: Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by restoring inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent is preferably a biologic agent such as an interleukin.Type: ApplicationFiled: October 14, 2003Publication date: June 10, 2004Applicant: SuperGen, Inc.Inventors: Joseph Rubinfeld, Lucy Chang, Jorge DiMartino
-
Publication number: 20040097437Abstract: A method is provided for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation, the method comprising: administering to the patient an anthracycline for a period of time during which a 20(S)-camptothecin is not present in a pharmacologically active form in patient's blood; and administering a 20(S)-camptothecin to the patient.Type: ApplicationFiled: July 16, 2003Publication date: May 20, 2004Applicant: SuperGen, Inc., a Delaware CorporationInventor: Joseph Rubinfeld
-
Patent number: 6710195Abstract: A method is provided for preparing a pharmaceutical composition comprising: taking polyoxyethylated castor oil which if diluted 1:10 in water has a pH greater than 5 and aging the polyoxyethylated castor oil by exposing the polyoxyethylated castor oil to a gas comprising oxygen for a period of time, the exposure to the gas over the period of time causing an acidity of the polyoxyethylated castor oil to increase; and forming a pharmaceutical composition comprising the aged polyoxyethylated castor oil and a pharmaceutically active agent such as paclitaxel; wherein at least 80% of the potency of the pharmaceutically active agent is retained by the pharmaceutical composition after the pharmaceutical composition is stored for at least 7 days at 40° C.Type: GrantFiled: November 26, 2002Date of Patent: March 23, 2004Assignee: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Joseph Rubinfeld, Sanjeev Redkar, Ashok Y. Gore
-
Publication number: 20040052864Abstract: Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent such as monoclonal antibody and interferon.Type: ApplicationFiled: July 3, 2003Publication date: March 18, 2004Applicant: SuperGen, Inc.Inventors: Joseph Rubinfeld, Lucy Chang, Jorge DiMartino
-
Publication number: 20040014695Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.Type: ApplicationFiled: May 27, 2003Publication date: January 22, 2004Applicant: SuperGen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6664233Abstract: A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation such as cancer and restenosis is provided. The method comprises: delivering to the patient a therapeutically effective amount of 9-nitro-20(S)-camptothecin in combination with an effective amount of an antibiotic agent such as bleomycin.Type: GrantFiled: November 10, 2000Date of Patent: December 16, 2003Assignee: SuperGen, Inc.Inventor: Joseph Rubinfeld
-
Publication number: 20030191179Abstract: Methods are provided for using paclitaxel for treating diseases associated with abnormal cell proliferation and angiogenesis. In particular, methods are provided for administration of paclitaxel formulated with vitamin E derivatives such as d-&agr;-tocopherol polyethylene glycol succinate to a cancer patient. By administering to a patient paclitaxel in a vehicle containing a solubilizer other than Cremophor, acute hypersensitivity caused by Cremophor can be avoided and therapeutic index of paclitaxel may also be increased through potentiation of anti-neoplastic effects by the vitamin E derivatives.Type: ApplicationFiled: January 23, 2003Publication date: October 9, 2003Applicant: SuperGen, Inc.Inventors: Rajashree Joshi-Hangal, Howard Sands, Joseph Rubinfeld
-
Patent number: 6613753Abstract: Compositions and methods are provided for treating diseases associated with abnormal cell proliferation such as cancer by storing inherent tumor-suppressing functions of neoplastic cells through DNA hypomethylation. The method comprises: delivering to a patient suffering from cancer a therapeutically effective amount of a DNA methylation inhibitor such as decitabine, in combination with an effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation. The anti-neoplastic agent can be an alkylating agent, an antibiotic agent, an antimetabolic agent, a retinoid, a hormonal agent, a plant-derived agent, an anti-angiogenesis agent and a biologic agent such as monoclonal antibody and interferon.Type: GrantFiled: February 21, 2001Date of Patent: September 2, 2003Assignee: SuperGen, Inc.Inventors: Joseph Rubinfeld, Lucy Chang, Jorge DiMartino
-
Patent number: 6583125Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.Type: GrantFiled: August 23, 2001Date of Patent: June 24, 2003Assignee: SuperGen, Inc.Inventor: Joseph Rubinfeld
-
Patent number: 6509027Abstract: A pharmaceutical composition is provided which comprises an aqueous suspension of solid particles, the solid particles comprising a camptothecin, the solid particles having mean diameters between about 0.05 um and 10 um, the particles coated with a 0.3 nm to 3.0 um thick layer of a membrane-forming amphipathic lipid. The pharmaceutical composition is particularly well suited for delivering camptothecins, particularly 9-nitro-camptothecin intravenously.Type: GrantFiled: February 12, 2001Date of Patent: January 21, 2003Assignees: SuperGen, Inc., RTP Pharma Inc.Inventors: Howard Sands, Awadhesh Mishra